{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-233934","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.978768+00:00","generated_at":"2026-06-10T19:29:07.401883+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AN2 Therapeutics starts Phase 3 trial for epetraborole in refractory MAC lung disease","bullets":["Phase 2 enrollment completed with 80 patients; topline Phase 2 data expected summer 2024.","Phase 3 part launched with over 100 sites in U.S., Japan, South Korea, Australia; plans to enroll ~230 patients.","Epetraborole is an oral, once-daily drug; FDA granted Fast Track, QIDP, and orphan drug designations.","No approved oral therapy currently exists for MAC lung disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-233934","json":"https://secwatch.observer/filing/0001193125-23-233934.json","markdown":"https://secwatch.observer/filing/0001193125-23-233934.md","text":"https://secwatch.observer/filing/0001193125-23-233934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523233934/0001193125-23-233934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523233934/d545132d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:29:07.401883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}